医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead Bispecific Antibody Candidate towards Clinical Development

2017年05月31日 PM01:00
このエントリーをはてなブックマークに追加


 

SHANGHAI

EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and WuXi Biologics, a WuXi AppTec Affiliate, announced today a collaboration to advance EpimAb’s first candidate, EMB-01, towards IND-filing. EMB-01 is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. Under the agreement, WuXi will be responsible for establishing the chemistry, manufacturing and control (CMC) portion for the EMB-01 development program up to filing of the IND, which is expected in mid-2018.

“Our first proprietary drug candidate is on track to enter clinical development next year. We are very proud to have achieved this just about two years after establishing the company and shortly after our recently announced Series A financing,” said Dr. Chengbin Wu, CEO of EpimAb Biotherapeutics. “With a global leading biologics services provider like WuXi Biologics, offering comprehensive, integrated and highly customizable services, we are well positioned to keep up our high pace in developing and growing the value of EpimAb’s pipeline.”

“We are honored to enable innovative biotechnology companies such as EpimAb to expedite their first program into the clinic,” said Dr. Chris Chen, CEO of WuXi Biologics. “Through our global quality and integrated biologics platform, we strive to make life-saving biologics more affordable and available to global patients.”

EpimAb, which was founded in 2015 and recently raised $25M in Series A with an international investment consortium, has developed a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. The Company has established a broad preclinical pipeline of innovative bispecifics based on its FIT-Ig® platform. EpimAb’s lead oncology candidate EMB-01 has demonstrated favorable drug-like properties, production characteristics and preclinical efficacy in animal models.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit www.epimab.com

Meet Epimab at ChinaBio – Epimab will participate at the 9th Annual ChinaBio Partnering Forum, May 31–June 1, 2017, at the Zhuhai International Convention and Exhibit Center. Feel free to reach out if want to learn more about our FIT-Ig® platform and our pipeline.

About WuXi Biologics

WuXi Biologics, a WuXi AppTec Affiliate, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi’s Biologics services, please visit: http://www.wuxibiologics.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005652/en/

CONTACT

EpimAb Biotherapeutics
Dr. Stephan Lensky, COO/CBO
Direct:
+49 152 2610 7621
E-Mail: Stephan.lensky@epimab.com
or
Media
Inquieries

Mario Brkulj
Direct: +49 175 5010575
Main:
+49 89 24243494
E-Mail: mbrkulj@macbiocom.com
or
Dr.
Stephanie May
+49 175 5711562
+1 781 235 3060
smay@macbiocom.com
or
WuXi
Biologics

Jia Li
+86-21-2066-4528
li_jia0102@wuxiapptec.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
  • New Data Shows Previously Allergic Children Still Able to Tolerate Peanut Four Years after Treatment with a Novel Immunotherapy Licensed by Prota Therapeutics
  • Mannatech Australia Makes the Morning Healthier with New Nutrient-Rich Coffee
  • CDISC Releases Therapeutic Area User Guide to Assist in Discovery of New Treatments for Prostate Cancer
  • 迪拜卫生署部署Masimo Patient SafetyNet™